empagliflozin/linagliptin/metformin (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses


Diabetes Mellitus Type 2

Pending FDA approval as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Safety and efficacy not established



Mechanism of Action

Empagliflozin: SGLT2 inhibitor; SGLT2 is expressed in the proximal renal tubules and is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen; SGLT2 inhibitors reduce glucose reabsorption and lower the renal threshold for glucose, thereby increasing urinary glucose excretion

Linagliptin: DPP-4 inhibitor; increases and prolongs incretin hormone activity, which is inactivated by DPP-4 enzyme; incretins regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and reducing glucagon secretion from pancreatic alpha cells

Metformin: Decreases hepatic glucose production; decreases GI glucose absorption; increases target cell insulin sensitivity



Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.